Literature DB >> 20502567

Derivative and Q-analysis Spectrophotometric Methods for Estimation of Hydrochlorothiazide and Olmesartan Medoxomil in Tablets.

K P Bhusari1, P B Khedekar, Seema Dhole, V S Banode.   

Abstract

Two methods for simultaneous estimation of hydrochlorothiazide and olmesartan medoxomil in combined tablet dosage form have been developed. The first method is the application of Q-analysis method (absorbance ratio), which involves the formation of Q-absorbance equation at 264 nm (isobestic point) and at 271 nm, the maximum absorption of hydrochlorothiazide. The linearity ranges for hydrochlorothiazide and olmesartan medoxomil were 2.5-22.5 mug/ml and 4-36 mug/ml, respectively. The second method is based on the derivative spectrophotometric method at zero crossing wavelengths. The linearity ranges for hydrochlorothiazide and olmesartan medoxomil were 2.5-20 mug/ml and 4-32 mug/ml, respectively. The accuracy of the methods were assessed by recovery studies and was found to be 100.45% +/-0.4215 and 100.24% +/-0.3783 for absorbance ratio method and 99.39% +/-0.221 and 99.72% +/-0.11 for first derivative method, for hydrochlorothiazide and olmesartan medoxomil, respectively. These methods are simple, accurate and rapid, those require no preliminary separation and can therefore be used for routine analysis of both drugs in quality control laboratories.

Entities:  

Keywords:  Derivative and Q-analysis spectrophotometric methods; hydrochlorothiazide; olmesartan medoxomil

Year:  2009        PMID: 20502567      PMCID: PMC2866340          DOI: 10.4103/0250-474X.58176

Source DB:  PubMed          Journal:  Indian J Pharm Sci        ISSN: 0250-474X            Impact factor:   0.975


Hydrochlorothiazide (HCTZ), chemically 6-chloro-3,4-dihydro-2H-1,2,4-benzothiadi- azine-7-sulphonamide-1,1-dioxide, is a diuretic and antihypertensive drug, which inhibits the reabsorption of sodium and calcium at the beginning of distal convoluted tubules. The chemical structure of HCTZ is shown in fig. 1. The typical dose of HCTZ is 12.5 mg per day[1-5]. Literature survey revealed that HPLC, HPTLC and spectroscopic methods have been reported for its determination in combination with other drugs[6-17]. Olmesartan medoxomil (OLME), chemically (5-methyl-2-oxo-1,3-dioxolen-4-yl)methyl-4-(1-hydroxyl-1-methylethyl)-2-propyl-1-[4-{2-(tetrazol-5-yl)-phenyl}-phenyl]methylimidaz-ole-5-carboxylate is a prodrug used as antihypertensive, which blocks the vasoconstrictor effect of angiotensin-II by selectively blocking the binding of angiotensin-II to the AT1 receptor in vascular smooth muscle[18-21]. Literature survey reveals that capillary zone electrophoresis method is reported for its estimation alone and HPTLC method has been reported for its estimation in combination with HCTZ[2223]. The dose of OLME is 20 mg daily and its structure is shown in fig. 2. A combination of drugs, HCTZ (12.5 mg) and OLME (20 mg) in tablet formulation is available commercially (Olmezest-H 20, Sun Pharmaceutical Industries Ltd., Mumbai, India). However, no spectrophotometric method has yet been reported for simultaneous estimation of HCTZ and OLME. Hence, an attempt has been made to develop and validate, in accordance with ICH guidelines, a simple, precise, accurate and economical spectrophotometric method for quantitative analysis of HCTZ and OLME in combined tablets[2425].
Fig. 1

Hydrochlorothiazide

Fig. 2

Olmesartan medoxomil

Hydrochlorothiazide Olmesartan medoxomil

MATERIALS AND METHODS

Pharmaceutically pure sample of HCTZ and OLME were obtained as generous gifts from Golden Cross Pvt. Ltd., Daman, India and MSN Laboratories Pvt. Ltd., Medak, India, respectively. Methanol AR grade (Merck Ltd., Mumbai, India) was used as solvent in the study. Double beam UV/Vis spectrophotometer, Shimadzu model 1601 with a pair of 10 mm matched quartz cells was used to measure absorbance of the resulting solution.

Preparation of standard stock solution:

Accurately, 50 mg each of HCTZ and OLME was weighed separately and transferred to two different 50 ml volumetric flask. Each drug was dissolved in methanol and volume was made up to the mark with methanol. The standard stock solution (1000 μg/ml) were further diluted separately to obtain working standard solution of concentration 7.5 μg/ml of HCTZ and 12.0 μg/ml of OLME.

Study of spectra and selection of wavelengths:

Each working standard solution was scanned between the range 200-400 nm in 1 cm cell against blank. The zero and first order derivative absorption spectra were recorded. Two wavelengths were selected from the overlain zero order spectra (fig. 3), 264 nm (Isobestic point) and 271 nm (λmax of HCTZ) for formation of Q-absorbance equation. The peak amplitude of first derivative spectra (fig. 4) was measured at 254.5 nm and 269.5 nm for HCTZ and OLME, respectively.
Fig. 3

Overlain spectra of hydrochlorothiazide and olmesartan medoxomil

I is hydrochlorothiazide; II is olmesartan medoxomil; III is isobestic point (264 nm) and IV is the λmax of hydrochlorothiazide (271 nm).

Fig. 4

Overlain first order derivative spectra of hydrochlorothiazide and olmesartan medoxomil

I is hydrochlorothiazide; II is olmesartan medoxomil; III and IV are zero crossing points of hydrochlorothiazide (269.5 nm) and olmesartan medoxomil (254.5 nm), respectively.

Overlain spectra of hydrochlorothiazide and olmesartan medoxomil I is hydrochlorothiazide; II is olmesartan medoxomil; III is isobestic point (264 nm) and IV is the λmax of hydrochlorothiazide (271 nm). Overlain first order derivative spectra of hydrochlorothiazide and olmesartan medoxomil I is hydrochlorothiazide; II is olmesartan medoxomil; III and IV are zero crossing points of hydrochlorothiazide (269.5 nm) and olmesartan medoxomil (254.5 nm), respectively.

Procedure for analysis of tablet formulation:

Twenty tablets were accurately weighed and average weight was calculated. The tablets were triturated to a fine powder. An accurately weighed quantity of powder equivalent to 60 mg of OLME was dissolved in methanol and volume was made up to 50 ml. The solution was filtered through Whatmann filter paper No. 41 and aliquot portion of filtrate was diluted to produce solution of 7.5 μg/ml of HCTZ and 12 μg/ml of OLME. The absorbance of sample solution was measured at selected wavelengths and the concentrations of the two drugs were estimated using absorbance ratio and first order derivative methods. The analysis procedure was repeated six times and the results are depicted in Table 1.
TABLE 1

RESULTS OF ANALYSIS OF TABLET FORMULATION

DrugsQ-analysis method % ±SD (n=6)First order derivative method % ±SD (n=6)
HCTZ100.23±0.36099.86±0.428
OLME100.34±0.41699.90±0.486

SD is standard deviation. HCTZ is hydrochlorothiazide and OLME is olmesartan medoxomil.

RESULTS OF ANALYSIS OF TABLET FORMULATION SD is standard deviation. HCTZ is hydrochlorothiazide and OLME is olmesartan medoxomil.

RESULTS AND DISCUSSION

In quantitative estimation of two components by Q-analysis method, absorbances were measured at the isobestic wavelength and maximum absorption wavelength of one of the two drugs. From overlain spectra of HCTZ and OLME (fig. 3), absorbances were measured at the selected wavelengths i.e., 264 nm (isobestic point) and at 271 nm, the maximum absorption of HCTZ. The absorptivity coefficients of each drug at both wavelengths were determined. The concentration of each drug in laboratory mixture and tablet formulation was determined by substituting the absorbance and absorptivity coefficients in the following sets of equations, Cx= Qm-Qy/Qx-Qy×A/Ax1 (Eqn. 1) and Cy= Qm-Qx/Qy-Qx×A/Ay1 (Eqn. 2), where, Cx is the concentration of HCTZ, Cy is the concentration of OLME, Qm is the ratio of absorbance of sample at selected wavelengths, Qx is the ratio of absorptivity coefficients of HCTZ, Qy is the ratio of absorptivity coefficients of OLME, Ax1 is absorptivity coefficient of HCTZ at 264 nm, Ay1 is absorptivity coefficient of OLME at 264 nm. Upon examining the first derivative spectra of the two drugs (fig. 4), it can be noticed that HCTZ can be determined at 254.5 nm where OLME has no contribution and OLME can be determined at 269.5 nm where HCTZ shows a zero crossing. The concentrations of drugs were determined from the standard calibration curve of HCTZ and OLME, respectively by interpolation method. A= 0.0028c+0.0009, r= 0.9977 (λ= 254.5nm) (Eqn. 3) and A= 0.0016c+0.0002, r= 0.9998 (λ= 269.5nm) (Eqn. 4), where, c is the concentration in μg/ml, A is the peak amplitude of the first derivative curves at 254.5 nm and 269.5 nm for HCTZ and OLME respectively, r is correlation coefficient. The peak amplitude of first derivative spectra was measured at 254.5 nm and 26.5 nm for HCTZ and OLME, respectively. The amount of the two drugs was calculated from the computed regression Eqns. 3 and 4. The results are depicted in Table 1. The methods were validated with respect to linearity, limit of detection (LOD), limit of quantification (LOQ), precision, accuracy and ruggedness. To study accuracy of the developed methods, recovery studies were carried out using standard addition method at three different levels. Percent recovery and low relative standard deviation value shows accuracy of the spectrophotometric methods. For precision of methods, the relative standard deviation for six replicates of sample solution was less than 2%, which met the acceptance criteria established for s pectrophotometric methods. Ruggedness of the proposed method was determined by analysis of sample solution prepared by proposed methods between different days and analysts. The percent relative standard deviation reported was found to be less than 2% showed ruggedness of the s pectrophotometric methods. The results obtained are summarized in Tables 2 and 3.
TABLE 2

RESULTS OF RECOVERY STUDIES IN TABLET FORMULATION

MethodSpike level (μg/ml)Percent recovery % ± SD (n=6)


HCTZOLMEHCTZOLME
I1.52.4100.40±0.420100.19±0.371
II1.52.499.18±0.21199.84±0.112
I3.04.8100.28±0.46399.88±0.391
II3.04.899.36±0.31299.62±0.231
I4.57.2100.35±0.388100.28±0.360
II4.57.299.62±0.20199.71±0.099

Method I is the Q-analysis method and Method II is the first order derivative. HCTZ is hydrochlorothiazide and OLME is olmesartan medoxomil.

TABLE 3

VALIDATION PARAMETERS

ParametersAbsorbance ratio methodFirst order derivative method


HCTZOLMEHCTZOLME
Slope0.0810.03250.0028−0.0016
Intercept0.01490.00380.000090.0002
Correlation coefficient0.99970.99980.99970.9997
Linearity range2.5-22.5 μg/ml4-36 μg/ml2.5-20 μg/ml4-32 μg/ml
LOD(μg/ml)0.580.610.60.7
LOQ(μg/ml)0.951.20.91.1
Precision (% RSD)0.3590.4140.4160.483
Intra day (n=3) %± SD100.33±0.088100.63±0.12199.70±0.71199.62±0.705
Inter day (n=3) %± SD99.78±0.22499.23±0.297100.22±0.890100.23±0.761
Different analyst (n=3) %± SD100.83±0.030100.26±0.06499.64±0.44299.61±0.457

LOD is limit of detection; LOQ is limit of quantification; % RSD is percentage relative standard deviation. HCTZ is hydrochlorothiazide and OLME is olmesartan medoxomil.

RESULTS OF RECOVERY STUDIES IN TABLET FORMULATION Method I is the Q-analysis method and Method II is the first order derivative. HCTZ is hydrochlorothiazide and OLME is olmesartan medoxomil. VALIDATION PARAMETERS LOD is limit of detection; LOQ is limit of quantification; % RSD is percentage relative standard deviation. HCTZ is hydrochlorothiazide and OLME is olmesartan medoxomil. The proposed UV spectrophotometric methods are a simple, accurate, precise, rapid and economical for the simultaneous estimation of HCTZ and OLME in tablet dosage form. The proposed methods use inexpensive reagents, solvents and instruments that are available in laboratories. Hence, these methods can be conveniently adopted for the routine analysis in quality control laboratories.
  9 in total

1.  Analysis of binary mixtures of losartan potassium and hydrochlorothiazide by using high performance liquid chromatography, ratio derivative spectrophotometric and compensation technique.

Authors:  N Erk
Journal:  J Pharm Biomed Anal       Date:  2001-02       Impact factor: 3.935

2.  Simultaneous determination of hydrochlorothiazide and several inhibitors of angiotensin-converting enzyme by capillary electrophoresis.

Authors:  S Hillaert; K De Grauwe; W Van den Bossche
Journal:  J Chromatogr A       Date:  2001-07-27       Impact factor: 4.759

3.  Application of LC and HPTLC-densitometry for the simultaneous determination of benazepril hydrochloride and hydrochlorothiazide.

Authors:  A El-Gindy; A Ashour; L Abdel-Fattah; M M Shabana
Journal:  J Pharm Biomed Anal       Date:  2001-05       Impact factor: 3.935

4.  Simultaneous determination of amiloride HCl, hydrochlorothiazide and atenolol in combined formulations by derivative spectroscopy.

Authors:  C V Prasad; C Parihar; K Sunil; P Parimoo
Journal:  J Pharm Biomed Anal       Date:  1998-08       Impact factor: 3.935

5.  Stability study of losartan/hydrochlorothiazide tablets.

Authors:  Maja Lusina; Tanja Cindrić; Jadranka Tomaić; Marijana Peko; Lidija Pozaić; Nenad Musulin
Journal:  Int J Pharm       Date:  2004-12-28       Impact factor: 5.875

6.  Pharmacokinetics of olmesartan medoxomil plus hydrochlorothiazide combination in healthy subjects.

Authors:  Reinhold Kreutz; Juliane Bolbrinker; Matthias Huber
Journal:  Clin Drug Investig       Date:  2006       Impact factor: 2.859

7.  Sensitive and selective liquid chromatography-electrospray ionization tandem mass spectrometry analysis of hydrochlorothiazide in rat plasma.

Authors:  Takatoshi Takubo; Hiromasa Okada; Mikio Ishii; Ken-ichi Hara; Yasuyuki Ishii
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2004-07-05       Impact factor: 3.205

8.  Electrochemical study of hydrochlorothiazide and its determination in urine and tablets.

Authors:  Omayma Abdel Razak
Journal:  J Pharm Biomed Anal       Date:  2004-02-04       Impact factor: 3.935

9.  Spectrophotometric quantitative determination of cilazapril and hydrochlorothiazide in tablets by chemometric methods.

Authors:  Erdal Dinç; Dumitru Baleanu
Journal:  J Pharm Biomed Anal       Date:  2002-10-15       Impact factor: 3.935

  9 in total
  1 in total

1.  Application of a Stability-Indicating HPTLC Method for Simultaneous Quantitative Determination of Olmesartan Medoxomil and Hydrochlorothiazide in Pharmaceutical Dosage Forms.

Authors:  Kaliappan Ilango; Pushpangadhan S Shiji Kumar
Journal:  J Anal Methods Chem       Date:  2013-11-04       Impact factor: 2.193

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.